Literature DB >> 12558194

Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation.

R M Pinheiro1, J B Calixto.   

Abstract

OBJECTIVE: This study evaluates the action of celecoxib and rofecoxib, two selective cyclooxygenase-2 (COX-2) inhibitors in two acute models of inflammation, carrageenan (Cg)-induced rat pleurisy, and paw oedema formation. MATERIAL: Male Wistar rats (N = 4-10 per group) were used. A fixed volume of PBS or carrageenan was injected into the pleural cavity or into the paw. Furthermore, the myeloperoxidase (MPO) activity and the levels of nitrite/nitrate (NOx), interleukin-1beta (IL-1beta), tumor necrosis factor-a (TNF-a) and PGE2 were also assessed in the paw tissue or in pleural exudate.
RESULTS: Dexamethasone (DEX, 0.5 mg kg(-1), s.c., -4 h) and indomethacin (INDO, 3 mg kg(-1), p.o., -1 h) suppressed Cg-induced pleural exudate accumulation by 84 and 77% and inflammatory cell influx by 66 and 47%, respectively. In contrast, celecoxib (CLX, 10 mg kg(-1), p.o., -1 h) or rofecoxib (RFX, 10 mg kg(-1) , p.o., -1 h) only reduced the Cg-induced pleural exudate volume by 44 and 40%, respectively, but had no significant effect over inflammatory cell influx. At the same doses used for pleurisy, DEX, INDO, CLX, RFX and SC-560 (a selective COX-1 inhibitor, 40 mg kg(-1), p.o., -1 h), inhibited the Cg-induced paw oedema by 49, 31, 21, 21 and 17%. DEX, INDO or SC-560 reduced the level of MPO by 71, 78 and 59%, while CLX or RFX produced a small, but significant increase (28 or 16%) in MPO activity. In the rat model of pleurisy, PGE2 levels in cell-free exudates were significantly attenuated by 91, 89, 57 and 65% in animals treated with DEX, INDO, CLX or RFX. In contrast, INDO reduced significantly the whole bloodTXB, synthesis (59%) while DEX and INDO reduced the pleural content of NOx significantly. Treatment of animals with CLX or RFX did not alter the content of pro-inflammatory cytokines IL-1beta or TNF-alpha in the pleural exudate, but CLX reduced IL-1beta levels in the rat paw tissue and RFX increased TNF-alpha in this tissue.
CONCLUSION: Together these results provide consistent evidence indicating that the selective COX-2 inhibitors CLX and RFX, in contrast to DEX, INDO or SC-560, despite reducing greatly the Cg-induced pleural exudation, PGE2 content and paw oedema have only partial acute anti-inflammatory properties in two different rat acute models of inflammation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12558194     DOI: 10.1007/pl00012435

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  16 in total

1.  Diuretic and Anti-Inflammatory Activities of the Microencapsulated Acrocomia aculeata (Arecaceae) Oil on Wistar Rats.

Authors:  Caroline Honaiser Lescano; Renan Donomae Iwamoto; Eliana Janet Sanjinez-Argandoña; Cândida Aparecida Leite Kassuya
Journal:  J Med Food       Date:  2014-11-04       Impact factor: 2.786

2.  Comparative study of anti-inflammatory and ulcerogenic activities of different cyclo-oxygenase inhibitors.

Authors:  Alessandra Gambero; Tagliane Liza Becker; Andréa Silva Zago; Andréa Fermino de Oliveira; José Pedrazzoli
Journal:  Inflammopharmacology       Date:  2005       Impact factor: 4.473

Review 3.  COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date.

Authors:  Michael Riedel; Martin Strassnig; Markus J Schwarz; Norbert Müller
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

4.  Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.

Authors:  Ronald Esser; Carol Berry; Zhengming Du; Janet Dawson; Alyson Fox; Roger A Fujimoto; William Haston; Earl F Kimble; Julie Koehler; Jane Peppard; Elizabeth Quadros; Joseph Quintavalla; Karen Toscano; Laszlo Urban; John van Duzer; Xiaoli Zhang; Siyuan Zhou; Paul J Marshall
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

5.  Anethole and eugenol reduce in vitro and in vivo leukocyte migration induced by fMLP, LTB4, and carrageenan.

Authors:  Camila Fernanda Estevão-Silva; Raquel Kummer; Fernanda Carolina Fachini-Queiroz; Renata Grespan; Gessilda Alcântara Nogueira de Melo; Silmara Baroni; Roberto Kenji Nakamura Cuman; Ciomar Aparecida Bersani-Amado
Journal:  J Nat Med       Date:  2014-05-01       Impact factor: 2.343

6.  Relevance of tumour necrosis factor-alpha for the inflammatory and nociceptive responses evoked by carrageenan in the mouse paw.

Authors:  Ana C C Rocha; Elizabeth S Fernandes; Nara L M Quintão; Maria M Campos; João B Calixto
Journal:  Br J Pharmacol       Date:  2006-05-15       Impact factor: 8.739

7.  Molecular docking and pharmacological/toxicological assessment of a new compound designed from celecoxib and paracetamol by molecular hybridization.

Authors:  Daiany P B da Silva; Iziara F Florentino; Dayane M da Silva; Roberta C Lino; Carina S Cardoso; Lorrane K S Moreira; Géssica A Vasconcelos; Daniela C Vinhal; Anna C D Cardoso; Bianca Villavicencio; Hugo Verli; Boniek G Vaz; Luciano M Lião; Luiz C da Cunha; Ricardo Menegatti; Elson A Costa
Journal:  Inflammopharmacology       Date:  2018-07-23       Impact factor: 4.473

8.  Chemoprevention of gastric cancer by celecoxib in rats.

Authors:  P J Hu; J Yu; Z R Zeng; W K Leung; H L Lin; B D Tang; A H C Bai; J J Y Sung
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

9.  Can L(+)-lactate be used as a marker of experimentally induced inflammation in rats?

Authors:  Anja Finn; Sandra Claudine Oerther
Journal:  Inflamm Res       Date:  2009-10-28       Impact factor: 4.575

10.  Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents.

Authors:  Tiziano Croci; Marco Landi; Anne-Marie Galzin; Pietro Marini
Journal:  Br J Pharmacol       Date:  2003-07-29       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.